Pediatric Clinical Trials

Home › Research › Trials

Abatacept for Graft Versus Host Disease Prophylaxis after Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research Trial

MSD BMT for Less Severe SCD: HLA Matched Related Hematopoietic Stem Cell Transplantation for Children with Less Severe Sickle Cell Disease: a Sickle Transplant Alliance for Research (STAR) Trial

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

Post-transplant Cyclophosphamide in Alternative Donor Transplant for Sickle Cell

Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease

INCB 18424-365 – A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogenic stem cell transplantation (REACH 3)

INCB 18424-MA-GD-301: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

A phase II, open label, non-controlled, intrapatient dose deescalation study to charachterize the pharmakokinatics after oral administration of eltrombopag in pediatric patients with refractory, relapsed, or treatment naïve severe aplastic anemia or reccurnet aplastic anemia

BMT CTN Protocol 1502 Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (CHAMP)

A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease